SEC Comment Letter 0000000000-24-007869 to Kyverna Therapeutics, Inc. (KYTX)
Kyverna Therapeutics, Inc.
Date: July 11, 2024 · CIK: 0001994702 · Accession: 0000000000-24-007869
AI Filing Summary & Sentiment
Reasoning
Letter
July 11, 2024 Jean-Philippe Kouakou-Zebouah Chief Financial Officer Vida Ventures, LLC 40 Broad Street, Suite 201 Boston, MA 02109 Re:Vida Ventures, LLC Kyverna Therapeutics, Inc. Schedule 13D Filed By Vida Ventures, LLC et al. Filed May 3, 2024 File No. 005-94441 Dear Jean-Philippe Kouakou-Zebouah: We have reviewed the above-captioned filing and have the following comment. Please respond to this letter by amending the filing or by providing the requested information. If you do not believe our comment applies to your facts and circumstances or that an amendment is appropriate, please advise us why in a response letter. After reviewing any amendment to the filing and any information provided in response to this comment, we may have additional comments. Schedule 13D Filed May 3, 2024 General 1.We note the date of the event reported as requiring the filing of the Statement was February 12, 2024. Rule 13d-1(a) of Regulation 13D-G requires the filing of a Schedule 13D within five business days after the date beneficial ownership of more than five percent of a class of equity securities specified in Rule 13d-1(i)(1) was acquired. Based on the February 12, 2024 event date, the Schedule 13D submitted on May 3, 2024 was not timely filed. Please advise us why the Schedule 13D was not filed within the required five business days after the date of the acquisition.
July 11, 2024 Page 2 We remind you that the filing persons are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please direct any questions to Shane Callaghan at 202-551-6977 or Nicholas Panos at 202-551-3266. Sincerely, Division of Corporation Finance Office of Mergers & Acquisitions
Show Raw Text
July 11, 2024
Jean-Philippe Kouakou-Zebouah
Chief Financial Officer
Vida Ventures, LLC
40 Broad Street, Suite 201
Boston, MA 02109
Re:Vida Ventures, LLC
Kyverna Therapeutics, Inc.
Schedule 13D Filed By Vida Ventures, LLC et al.
Filed May 3, 2024
File No. 005-94441
Dear Jean-Philippe Kouakou-Zebouah:
We have reviewed the above-captioned filing and have the following comment.
Please respond to this letter by amending the filing or by providing the requested
information. If you do not believe our comment applies to your facts and circumstances or that an
amendment is appropriate, please advise us why in a response letter.
After reviewing any amendment to the filing and any information provided in response to
this comment, we may have additional comments.
Schedule 13D Filed May 3, 2024
General
1.We note the date of the event reported as requiring the filing of the Statement was
February 12, 2024. Rule 13d-1(a) of Regulation 13D-G requires the filing of a Schedule
13D within five business days after the date beneficial ownership of more than five
percent of a class of equity securities specified in Rule 13d-1(i)(1) was acquired. Based on
the February 12, 2024 event date, the Schedule 13D submitted on May 3, 2024 was not
timely filed. Please advise us why the Schedule 13D was not filed within the required five
business days after the date of the acquisition.
July 11, 2024
Page 2
We remind you that the filing persons are responsible for the accuracy and adequacy of
their disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please direct any questions to Shane Callaghan at 202-551-6977 or Nicholas Panos at
202-551-3266.
Sincerely,
Division of Corporation Finance
Office of Mergers & Acquisitions